Dr. Torsten Passie is a leading international expert on hallucinogenic drugs and author of The science of microdosing psychedelics
He joins an elite team of pharmacology and neuropsychiatry leaders on the Diamond Scientific Advisory Board
TORONTO, October 5, 2021 / PRNewswire / – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic therapies for use in the treatment of mental health, is pleased to announce the appointment of Dr. Torsten Passie to its scientific council.
Dr Passie is Professor of Psychiatry and Psychotherapy at Hanover Medical School in Hanover, Germany and an internationally recognized authority on the pharmacology and therapeutic use of psychedelics.
Dr Passie is also a visiting scholar at the Senckenberg Institute for the History and Ethics of Medicine in Goethe University Frankfurt. He is the former director of the Laboratory of Neurocognition and Consciousness at the Faculty of Medicine in Hanover and has carried out extensive research into the therapeutic potential of hallucinogenic drugs. Dr Passie has been a visiting professor at Harvard Medical School from 2012 to 2015.
Dr Passie has published extensively in prestigious scientific journals and is the author of The Science of Microdosing Psychedelics (2019). This book set the standard for understanding the microdosing of psychedelics such as psilocybin. Other books by Dr Passie include The Pharmacology of LSD (2010), Healing with Entactogens (2012) and The history of MDMA (2021).
“Diamond was the first company to generate valid data demonstrating that there is therapeutic potential from repeated low doses of psilocybin,” says Dr. Passie.
“It is a great honor to work with Diamond to further investigate the potential of low dose psychedelics to impact mental health treatments.”
“I am delighted to add Dr. Passie to Diamond’s already elite advisory board,” said Chairman Dr. Edouard Sellers. “Dr. Passie’s in-depth understanding of psychedelics and psychiatry will help advance Diamond’s plans to develop effective mental health treatments that are accessible to patients when proven effective and safe.”
Diamond Therapeutics’ Scientific Advisory Board includes an esteemed group of experts in neuroscience, pharmacology, psychiatry, drug discovery, and neuropsychiatric drug development, preclinical and clinical.
Dr. Edouard Sellers, professor emeritus of pharmacology, toxicology, medicine and psychiatry at the University of Toronto
Dr Paul Colle, Hazel Buckland Chair and Professor of Psychological Medicine at the Dunedin School of Medicine, University of Otago, New Zealand
Dr. Thomas kosten, JH Wagoner Chair and Professor of Psychiatry, Pharmacology, Immunology, Pathology and Neurosciences, Director Emeritus of the Dan L. Duncan Institute for Clinical and Translational Research at Baylor College of Medicine
Dr. Joseph moskal, Distinguished Research Professor and Director of the Falk Center for Molecular Therapeutics at Northwestern University
Dr. Torsten Passie, visiting researcher at the Senckenberg Institute of History and Ethics in Medicine, Goethe University Frankfurt and Professor of Psychiatry and Psychotherapy at the Hanover Faculty of Medicine, Germany
Dr. William J. Tyler, co-founder of IST LLC and Thync and associate professor in the School of Biological and Health Systems Engineering at Arizona State University
About Diamond Therapeutics
Diamond Therapeutics is a psychedelic drug development company based in Toronto.
Our mission is to develop new and better therapies for mental health issues by
unlock the promise of psychedelics. Diamond focuses on the sub-
perceptual, non-hallucinogenic treatments that have potential for wide use
patient cohort – maximizing the positive impact that better medicines can have on the world
mental health crisis. To learn more about Diamond, visit www.diamondthera.com.
Cautions Regarding Forward-Looking Information
This press release includes certain “forward-looking information” under applicable Canadian securities legislation. Forward-looking information includes statements other than statements of historical fact which may be identified by phrases such as “expects”, “anticipates”, “intention”, “objectives”, “plans” and ” believe ”and are based on expectations, estimates and projections as of the date of this press release. Forward-looking statements contained in this press release include, but are not limited to, the potential effects of low dose psilocybin and other psychedelic treatments, the potential use in the treatment of mental health problems, and the timing and l completion of Diamond’s clinical trials and programs. Forward-looking information is necessarily based on a number of estimates and assumptions which, while believed to be reasonable, are subject to known and unknown risks, uncertainties and other factors that may cause actual results to occur. and future events differ materially from those expressed or implied. by such forward-looking statements. These factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; delay or failure to receive applicable regulatory approvals; whereas factors may arise that may hamper Diamond’s future business plans; the results of further development, marketing and sales; and other factors beyond Diamond’s control. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Therefore, readers should not place undue reliance on forward-looking information. Diamond disclaims any intention or obligation to update or revise any forward-looking information contained in this press release, whether as a result of new information, future events or otherwise, except as required by law.
View original content to download multimedia: https://www.prnewswire.com/news-releases/diamond-therapeutics-appoints-renowned-psychiatrist-and-author-dr-torsten-passie-to-scientific-advisory-board -301392499 .html
SOURCE Diamond Therapeutics Inc.